TitleUse of transgenic and mutant animal models in the study of heterocyclic amine-induced mutagenesis and carcinogenesis.
Publication TypeJournal Article
Year of Publication2003
AuthorsDashwood RH
JournalJ Biochem Mol Biol
Volume36
Issue1
Pagination35-42
Date Published2003 Jan 31
ISSN1225-8687
KeywordsAdenomatous Polyposis Coli Protein, Amines, Animals, beta-Galactosidase, Cell Transformation, Neoplastic, Chemoprevention, Disease Models, Animal, DNA-Binding Proteins, Heterocyclic Compounds, Mice, Mice, Knockout, Mice, Mutant Strains, Mice, Transgenic, Mutagenesis, MutS Homolog 2 Protein, Neoplasms, Experimental, Proto-Oncogene Proteins, Ribosomal Proteins, Tumor Suppressor Protein p53, Xeroderma Pigmentosum Group A Protein
Abstract

Heterocyclic amines (HCAs) are potent mutagens generated during the cooking of meat and fish, and several of these compounds produce tumors in conventional experimental animals. During the past 5 years or so, HCAs have been tested in a number of novel in vivo murine models, including the following: lacZ, lacI, cII, c-myc/lacZ, rpsL, and gptDelta. transgenics, XPA-/-, XPC-/-, Msh2+/-, Msh2-/- and p53+/- knock-outs, Apc mutant mice (ApcDelta716, Apc1638N, Apcmin), and A33DeltaNbeta-cat knock-in mice. Several of these models have provided insights into the mutation spectra induced in vivo by HCAs in target and non-target organs for tumorigenesis, as well as demonstrating enhanced susceptibility to HCA-induced tumors and preneoplastic lesions. This review describes several of the more recent reports in which novel animal models were used to examine HCA-induced mutagenesis and carcinogenesis in vivo, including a number of studies which assessed the inhibitory activities of chemopreventive agents such as 1,2-dithiole-3-thione, conjugated linoleic acids, tea, curcumin, chlorophyllin-chitosan, and sulindac.

Alternate JournalJ. Biochem. Mol. Biol.
PubMed ID12542973
PubMed Central IDPMC2267881
Grant ListR01 CA080176-03 / CA / NCI NIH HHS / United States
R01 CA080176 / CA / NCI NIH HHS / United States
CA80176 / CA / NCI NIH HHS / United States
R29 CA065525 / CA / NCI NIH HHS / United States
R01 CA065525 / CA / NCI NIH HHS / United States
R01 CA065525-08 / CA / NCI NIH HHS / United States
R01 CA080176-02 / CA / NCI NIH HHS / United States
R01 CA065525-09 / CA / NCI NIH HHS / United States
R01 CA080176-05 / CA / NCI NIH HHS / United States
CA65525 / CA / NCI NIH HHS / United States
R01 CA065525-07 / CA / NCI NIH HHS / United States
R01 CA080176-04 / CA / NCI NIH HHS / United States
R01 CA065525-06A1 / CA / NCI NIH HHS / United States